See more : Marui Group Co., Ltd. (MAURF) Income Statement Analysis – Financial Results
Complete financial analysis of Medicure Inc. (MCUJF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicure Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- NanJing Sanchao Advanced Materials Co.,Ltd. (300554.SZ) Income Statement Analysis – Financial Results
- Thoughtworks Holding, Inc. (TWKS) Income Statement Analysis – Financial Results
- Cvent Holding Corp. (CVT) Income Statement Analysis – Financial Results
- Oasis Petroleum Inc (WLL) Income Statement Analysis – Financial Results
- Nippon Chemical Industrial Co., Ltd. (4092.T) Income Statement Analysis – Financial Results
Medicure Inc. (MCUJF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medicure.com
About Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.69M | 23.07M | 21.74M | 11.61M | 20.17M | 29.11M | 27.13M | 37.78M | 22.08M | 5.05M | 2.60M | 4.80M | 3.63M | 3.32M | 4.79M | 2.25M | 5.94M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
| Cost of Revenue | 7.71M | 6.99M | 9.03M | 6.48M | 7.27M | 4.15M | 3.46M | 9.77M | 2.26M | 868.12K | 665.90K | 1.07M | 673.52K | 571.69K | 377.08K | 605.62K | 387.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 13.99M | 16.08M | 12.71M | 5.13M | 12.90M | 24.96M | 23.67M | 28.01M | 19.82M | 4.18M | 1.94M | 3.73M | 2.95M | 2.75M | 4.42M | 1.64M | 5.56M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
| Gross Profit Ratio | 64.48% | 69.69% | 58.46% | 44.19% | 63.95% | 85.74% | 87.23% | 74.14% | 89.77% | 82.81% | 74.42% | 77.71% | 81.44% | 82.77% | 92.13% | 73.05% | 93.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 2.41M | 2.75M | 1.80M | 3.30M | 4.35M | 6.68M | 5.15M | 5.09M | 4.87M | 688.67K | 1.70M | 1.04M | 204.69K | 393.39K | 22.71K | 28.66M | 23.34M | 10.22M | 13.56M | 4.28M | 3.12M | 3.05M | 2.48M |
| General & Administrative | 4.13M | 4.19M | 2.70M | 4.58M | 3.40M | 19.50M | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.31M | 7.94M | 10.31M | 5.36M | 13.40M | 15.58M | 11.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.44M | 12.13M | 13.01M | 9.94M | 16.79M | 19.50M | 14.87M | 16.23M | 10.24M | 3.33M | 2.32M | 2.67M | 2.82M | 4.47M | 9.26M | 12.07M | 11.05M | 2.86M | 2.26M | 2.11M | 1.28M | 949.57K | 879.91K |
| Other Expenses | -854.00K | 346.00K | 1.83M | 0.00 | -3.62M | -1.47M | 82.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 898.93K | 612.52K | 372.80K | 2.65M | 2.29M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 12.58K |
| Operating Expenses | 13.99M | 14.88M | 14.81M | 13.24M | 21.14M | 26.18M | 20.02M | 21.33M | 15.10M | 4.02M | 4.02M | 3.72M | 3.92M | 5.48M | 9.65M | 43.39M | 36.67M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
| Cost & Expenses | 22.55M | 21.87M | 23.84M | 19.72M | 28.42M | 30.34M | 23.48M | 31.10M | 17.36M | 4.89M | 4.69M | 4.79M | 4.60M | 6.05M | 10.03M | 43.99M | 37.06M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
| Interest Income | 75.00K | 10.00K | 78.00K | 43.00K | 886.00K | 1.11M | 0.00 | 0.00 | 0.00 | 41.00 | 152.00 | 775.00 | 473.00 | 4.91K | 255.71K | 1.15M | 1.59M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 183.91K |
| Interest Expense | 10.00K | 0.00 | 38.00K | 49.00K | 22.00K | 53.68K | 90.00K | 208.64K | 367.27K | 415.84K | 418.07K | 553.73K | 3.12M | 3.28M | 4.94M | 3.83M | 1.96M | 400.87K | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.17M | 2.06M | 3.15M | 2.77M | 1.92M | 299.18K | 97.79K | 1.43M | 690.93K | 561.27K | 536.98K | 877.55K | 898.93K | 919.21K | 938.73K | 2.98M | 2.50M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 17.45K |
| EBITDA | 1.29M | 2.87M | 2.42M | -4.02M | -8.81M | -927.00K | 10.35M | 6.39M | 5.41M | 1.86M | -957.03K | -1.49M | -67.62K | -2.29M | -1.33M | -4.30M | -38.76M | -28.62M | -12.78M | -15.43M | -5.95M | -4.16M | -3.81M |
| EBITDA Ratio | 5.96% | 14.59% | 11.82% | -38.88% | -43.65% | -4.60% | 43.63% | 17.98% | 7.34% | -12.35% | -62.33% | 18.50% | -1.86% | -69.15% | -18.88% | -1,147.53% | -477.65% | -4,196.11% | -3,345.27% | -1,335.26% | -1,724.36% | -2,074.13% | -2,365.94% |
| Operating Income | -854.00K | 1.31M | -574.00K | -7.29M | -10.73M | -1.23M | 3.65M | 6.68M | 4.72M | 164.42K | -2.09M | 10.09K | -1.25M | -3.50M | -6.99M | -41.74M | -31.12M | -12.89M | -15.42M | -5.99M | -4.19M | -3.88M | -3.23M |
| Operating Income Ratio | -3.94% | 5.68% | -2.64% | -62.76% | -53.18% | -4.21% | 13.46% | 17.69% | 21.38% | 3.26% | -80.17% | 0.21% | -34.38% | -105.66% | -145.88% | -1,857.66% | -523.41% | -4,298.81% | -3,357.87% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
| Total Other Income/Expenses | -43.00K | 192.00K | -185.00K | 1.70M | -11.40M | 6.05M | -1.22M | -2.89M | -3.43M | 1.89M | 152.42K | -487.79K | 23.38M | -1.01M | -2.03M | 6.99M | 10.41M | 18.03M | -200.44K | -1.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -897.00K | 1.39M | -759.00K | -6.85M | -19.64M | 4.82M | 2.44M | 28.46M | 1.29M | -1.64M | -2.57M | 23.39M | -2.01M | -2.26M | -8.63M | -54.72M | -31.34M | -13.09M | -15.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4.13% | 6.00% | -3.49% | -58.96% | -97.36% | 16.57% | 8.98% | 75.33% | 5.84% | -32.45% | -98.91% | 487.53% | -55.51% | -68.07% | -180.01% | -2,435.16% | -527.12% | -4,365.68% | -3,357.87% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 25.00K | 20.00K | -32.00K | 49.00K | 145.00K | 896.88K | -9.06M | 802.83K | -379.00K | 38.20K | -3.01K | -23.93M | -2.07M | -959.99K | 6.53M | 24.81M | -1.15M | -478.47K | -553.34K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -922.00K | 1.37M | -727.00K | -6.89M | -19.79M | 3.93M | 43.42M | 27.66M | 1.67M | -1.64M | -2.57M | 23.39M | -2.01M | -5.53M | -13.32M | -57.40M | -31.70M | -12.61M | -14.87M | -5.99M | -4.19M | -3.88M | -3.23M |
| Net Income Ratio | -4.25% | 5.92% | -3.34% | -59.38% | -98.08% | 13.49% | 160.03% | 73.21% | 7.56% | -32.45% | -98.91% | 487.53% | -55.51% | -166.79% | -277.85% | -2,554.48% | -533.30% | -4,206.05% | -3,237.37% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
| EPS | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.25 | 2.78 | 1.80 | 0.12 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.69 | -2.10 | -3.00 |
| EPS Diluted | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.24 | 2.39 | 1.56 | 0.11 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.67 | -2.10 | -3.00 |
| Weighted Avg Shares Out | 10.24M | 10.25M | 10.25M | 10.69M | 15.00M | 15.79M | 15.64M | 15.00M | 13.46M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.47M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 10.44M | 10.44M | 10.25M | 10.69M | 15.00M | 16.56M | 18.14M | 17.32M | 15.77M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.50M | 1.85M | 1.08M |
MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST
WINNIPEG, MB , April 26, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market,...
MedX Health launches DermSecure screening services at Medicure clinic in Mississauga, Ontario
MedX Health Corp revealed that it is now offering its DermSecure screening services at the Medicure (TSX-V:MPH) clinic in Mississauga, Ontario - the first launch of its platform in a blended physician and pharmacy clinic setting in Canada. Under the...
Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript
Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript
Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021
WINNIPEG, MB, Aug. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021. Quarter Ended June 30, 2021 Highlights: Recorded...
Medicure Announces Grant of Stock Options
WINNIPEG, MB, July 30, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that...
Medicure Announces Appointment of David Gurvey as Chief Financial Officer
WINNIPEG, MB, June 24, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is...
Medicure Inc.(MCUJF) CEO Albert Friesen on Q1 2021 Results - Earnings Call Transcript
Medicure Inc.(MCUJF) CEO Albert Friesen on Q1 2021 Results - Earnings Call Transcript
Medicure Reports Financial Results for Quarter Ended March 31, 2021
WINNIPEG, May 10, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results...
Source: https://incomestatements.info
Category: Stock Reports